Kalaris Therapeutics Inc
NASDAQ: KLRS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Oxtoby
- Employees
- 14
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $82.3M
- Website
- https://kalaristx.com
Loading KLRS…
Loading profile data…Frequently asked questions about KLRS
What does Kalaris Therapeutics Inc (KLRS) do?
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.
Where does KLRS trade?
Kalaris Therapeutics Inc (KLRS) trades on the NASDAQ Global Market.
What sector is KLRS in?
Kalaris Therapeutics Inc (KLRS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kalaris Therapeutics Inc?
Andrew Oxtoby is the chief executive officer of Kalaris Therapeutics Inc (KLRS).
Where is Kalaris Therapeutics Inc headquartered?
Kalaris Therapeutics Inc is headquartered in United States.
Does KLRS pay a dividend?
Kalaris Therapeutics Inc (KLRS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KLRS go public?
Kalaris Therapeutics Inc (KLRS) completed its initial public offering in 2020.